Bristol-Myers Squibb K.K. said on June 22 that its affiliate Celgene K.K. has filed the CAR-T cell therapy lisocabtagene maraleucel (JCAR017/liso-cel) in Japan for the treatment of relapsed/refractory large B-cell lymphoma. The submission made under the category of regenerative medicine…
To read the full story
Related Article
- Celgene’s Liso-Cel Up for PAFSC Review on Feb. 17, 3rd CAR-T Therapy in Japan
February 4, 2021
- Celgene’s CAR-T Therapy Earns Orphan Status in Japan
October 10, 2018
BUSINESS
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
- Meiji’s Hiyasta Earns Approval in Thailand
July 21, 2026
- US FDA Accepts Shionogi’s Pediatric Fetroja Filing
July 21, 2026
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





